Naoya Niwa

Naoya Niwa

Auto-generated profile, based on publicly available information

Naoya Niwa

Department of Urology, Keio University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2020 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
NTNobuyuki Tanaka
Nobuyuki Tanaka
SKShigeaki Kanatani
Shigeaki Kanatani
DKDagmara Kaczynska
Dagmara Kaczynska
KFKeishiro Fukumoto
Keishiro Fukumoto
LLLauri Louhivuori
Lauri Louhivuori
PUPer Uhlen
Per Uhlen

1 June 2018 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
NNNaoya Niwa
Naoya Niwa
KMKazuhiro Matsumoto
Kazuhiro Matsumoto
HIHiroki Ide
Hiroki Ide
HNHirohiko Nagata
Hirohiko Nagata
MOMototsugu Oya
Mototsugu Oya

3 November 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
NTNobuyuki Tanaka
Nobuyuki Tanaka
TKTakeo Kosaka
Takeo Kosaka
YMYasumasa Miyazaki
Yasumasa Miyazaki
SMShuji Mikami
Shuji Mikami
NNNaoya Niwa
Naoya Niwa
MOMototsugu Oya
Mototsugu Oya
To identify the molecules involved in epithelial to mesenchymal transition (EMT) in urothelial carcinoma (UC) after acquisition of platinum resistance, here we examined the changes in global gene expression before and after platinum treatment. Four invasive UC cell lines, T24, 5637, and their corresponding sublines T24PR and 5637PR with acquired platinum resistance, were assessed by microarray, and the ubiquitin E3 ligase FBXO32 was newly identified as a negative regulator of EMT in UC tumors after acquisition of platinum resistance. In vitro and in vivo studies showed an intimate relationship between FBXO32 expression and EMT, demonstrating that FBXO32 dysregulation in T24PR cells results in elevated expression of the mesenchymal molecules SNAIL and vimentin and decreased expression of the epithelial molecule E-cadherin. The association between FBXO32 expression and EMT was further validated using clinical samples. Knockdown of MyoD expression, a specific target of FBXO32 polyubiquitination, revealed upregulation of E-cadherin expression and downregulation of SNAIL and vimentin expression in T24PR cells. Comparative genomic hybridization array analysis demonstrated loss of heterozygosity at 8q24.13 in T24PR cells, which harbors FBXO32. Our findings suggest the importance of the association between EMT and ubiquitin-proteasome regulation when tumors develop acquired platinum resistance.

22 March 2015 in Acta Oncologica
Verified
Journal Article
Closed access
PDF file
NNNaoya Niwa
Naoya Niwa
TNToru Nishiyama
Toru Nishiyama
COChoichiro Ozu
Choichiro Ozu
YYYasuto Yagi
Yasuto Yagi
SSShiro Saito
Shiro Saito
To the Editor, Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3, and has been approved for the treatment of advanced r...

1 September 2015 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
NNNaoya Niwa
Naoya Niwa
KMKazuhiro Matsumoto
Kazuhiro Matsumoto
NHNozomi Hayakawa
Nozomi Hayakawa
YIYujiro Ito
Yujiro Ito
TMTakahiro Maeda
Takahiro Maeda
NTNobuyuki Tanaka
Nobuyuki Tanaka

1 November 2018 in Brachytherapy
Verified
Journal Article
Closed access
NNNaoya Niwa
Naoya Niwa
KMKazuhiro Matsumoto
Kazuhiro Matsumoto
TNToru Nishiyama
Toru Nishiyama
YYYasuto Yagi
Yasuto Yagi
COChoichiro Ozu
Choichiro Ozu
MOMototsugu Oya
Mototsugu Oya